Amarin receives European Commission approval for Vazkepa to reduce cardiovascular events.

Amarin Corporation plc announced that following a review and approval recommendation by the European Medicines Agency (EMA), the European Commission (EC) has approved the marketing authorization application for Vazkepa (icosapent ethyl) to reduce the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides ( greater than 150 mg/dL) and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor. Amarin’s icosapent ethyl was approved for cardiovascular risk reduction by the FDA in December 2019 and is marketed in the U.S. under the brand name, Vascepa.